Eiger Biopharmaceuticals (NASDAQ:EIGR) has been assigned a $26.00 target price by investment analysts at Oppenheimer in a research report issued to clients and investors on Thursday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Oppenheimer’s price objective indicates a potential upside of 116.31% from the stock’s previous close.

EIGR has been the topic of several other research reports. ValuEngine downgraded shares of Eiger Biopharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, October 8th. Zacks Investment Research raised shares of Eiger Biopharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $12.00 target price on the stock in a research note on Monday. Wedbush set a $53.00 target price on shares of Eiger Biopharmaceuticals and gave the company a “buy” rating in a research note on Monday, August 13th. Finally, LADENBURG THALM/SH SH set a $28.00 target price on shares of Eiger Biopharmaceuticals and gave the company a “buy” rating in a research note on Wednesday. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Eiger Biopharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $30.13.

Shares of EIGR traded up $0.35 during midday trading on Thursday, hitting $12.02. The stock had a trading volume of 502,600 shares, compared to its average volume of 138,964. Eiger Biopharmaceuticals has a 1 year low of $7.46 and a 1 year high of $18.00. The company has a market cap of $170.93 million, a P/E ratio of -2.47 and a beta of 1.81. The company has a current ratio of 8.49, a quick ratio of 8.49 and a debt-to-equity ratio of 0.35.

Eiger Biopharmaceuticals (NASDAQ:EIGR) last announced its earnings results on Friday, August 10th. The biotechnology company reported ($0.82) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.82). Analysts predict that Eiger Biopharmaceuticals will post -3.19 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp grew its holdings in shares of Eiger Biopharmaceuticals by 36.8% in the second quarter. Bank of New York Mellon Corp now owns 20,412 shares of the biotechnology company’s stock worth $249,000 after purchasing an additional 5,492 shares during the last quarter. Algert Global LLC bought a new position in shares of Eiger Biopharmaceuticals in the second quarter worth about $277,000. Northern Trust Corp grew its holdings in shares of Eiger Biopharmaceuticals by 169.7% in the first quarter. Northern Trust Corp now owns 29,376 shares of the biotechnology company’s stock worth $289,000 after purchasing an additional 18,483 shares during the last quarter. Ardsley Advisory Partners bought a new position in shares of Eiger Biopharmaceuticals in the second quarter worth about $305,000. Finally, Essex Investment Management Co. LLC bought a new position in shares of Eiger Biopharmaceuticals in the third quarter worth about $619,000. 69.28% of the stock is currently owned by institutional investors and hedge funds.

Eiger Biopharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.

Featured Article: Dow Jones Industrial Average (DJIA)

Analyst Recommendations for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.